The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.

Some oncologists are turning to GLP-1 agents to help patients shed excess pounds, with the goal of improving cancer outcomes. But data on the practice remain limited.

Expanding Medicare to cover weight loss drugs would cost $35 billion over eight years, according to a new report from the Congressional Budget Office (CBO). In its estimates released Tuesday, CBO

The U.S. Food and Drug Administration (FDA) has agreed to reconsider its decision to remove tirzepatide, the active ingredient of Eli Lilly's (NYSE:LLY) diabetes therapy Mounjaro and weight loss therapy Zepbound,